Metropolis Healthcare shares soar 5% on acquiring Ambika Pathology; check details

At around 3:04 pm, the stock was trading 4.01% higher at ₹2,129.20 per equity share.

This comes after the diagnostic chain completed the acquisition of Kolhapur’s Ambika Pathology Laboratory through a business transfer agreement, its fourth acquisition in the past 10 months, Metropolis said in a regulatory filing on Thursday.

With the completion of the acquisition, Ambika Pathology has joined the Metropolis network, it stated.

The company plans to develop the newly acquired entity into a mini-regional reference lab, offering over 4,000 advanced and speciality diagnostics to patients in Kolhapur and neighbouring tier two and tier three towns, the filing added.

The acquisition marks a key milestone in its “String of Pearls” strategy, which is focused on building strong regional clusters and expanding access to advanced diagnostics across India, it stated.

Commenting on the acquisition, Surendran Chemmenkotil, Managing Director of Metropolis Healthcare Limited, said: “Our network expansion, through both organic and inorganic growth, is a strategic step towards reshaping how diagnostics is delivered in India. Kolhapur is an important healthcare hub, and the integration of Ambika Pathology Laboratory provides a formidable base to serve patients and clinicians more comprehensively.”

Ambika Pathology derives 75% of its revenue from B2C walk-in patients. Furthermore, it operates 19 laboratories across Pune, Kolhapur, Sangli, Satara, Solapur, Nashik, and Ahmednagar, with 200 patient service centres and a growing franchise network.

“The acquisition of Ambika Pathology further strengthens our Western Maharashtra cluster and supports our ambition to make high-quality diagnostics accessible to more communities,” said Ameera Shah, Promoter and Executive Chairperson at Metropolis.

In a separate regulatory filing this week, the diagnostic services provider incorporated the healthcare technology firm, Metropolis Quality Solutions Private Limited, as a wholly owned subsidiary.

The stock lost 0.45% over the week but has gained 32.04% over a period of six months. On a year-to-date basis, it surged 2.63%.

While the scrip reached a 52-week low of ₹1,315 on April 7, 2025, it touched a year’s high of ₹2,318.30 per equity share on October 10, 2024.

Metropolis Healthcare has a total market capitalisation of ₹10,960.90 crore, as of September 19, 2025, according to data on the NSE.